These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 11584998)
21. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center. Zhang G; Li XP; Liu BJ; Wang JL; Wang SJ; Cui H; Wei LH Chin Med J (Engl); 2013 Dec; 126(23):4477-82. PubMed ID: 24286410 [TBL] [Abstract][Full Text] [Related]
22. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815 [TBL] [Abstract][Full Text] [Related]
23. Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index. Hetland TE; Kærn J; Skrede M; Sandstad B; Tropé C; Davidson B; Flørenes VA Cancer Chemother Pharmacol; 2012 May; 69(5):1307-14. PubMed ID: 22302409 [TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer. Siddiqui GK; Maclean AB; Elmasry K; Wong te Fong A; Morris RW; Rashid M; Begent RH; Boxer GM Angiogenesis; 2011 May; 14(2):155-61. PubMed ID: 21221762 [TBL] [Abstract][Full Text] [Related]
25. Treatment of platinum-resistant ovarian cancer. Trimble EL; Wright J; Christian MC Expert Opin Pharmacother; 2001 Aug; 2(8):1299-306. PubMed ID: 11584998 [TBL] [Abstract][Full Text] [Related]
27. Cytoreductive surgery in the management of ovarian cancer. Schwartz PE Oncology (Williston Park); 2008 Aug; 22(9):1025-33; discussion 1033-8, 1041, 1045. PubMed ID: 18777954 [TBL] [Abstract][Full Text] [Related]
28. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Oronsky B; Ray CM; Spira AI; Trepel JB; Carter CA; Cottrill HM Med Oncol; 2017 Jun; 34(6):103. PubMed ID: 28444622 [TBL] [Abstract][Full Text] [Related]
29. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches. Lin H; Changchien CC Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343 [TBL] [Abstract][Full Text] [Related]
30. Review of dose-intense platinum and/or paclitaxel containing chemotherapy in advanced and recurrent epithelial ovarian cancer. Boere IA; van der Burg ME Curr Pharm Des; 2012; 18(25):3741-53. PubMed ID: 22591417 [TBL] [Abstract][Full Text] [Related]
31. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
32. Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer. Webber K; Friedlander M Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():126-138. PubMed ID: 28027849 [TBL] [Abstract][Full Text] [Related]
33. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? Tan DS; Kaye SB Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149 [TBL] [Abstract][Full Text] [Related]